scholarly journals Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia, Even with a Higher Leukemia Burden

2013 ◽  
Vol 19 (4) ◽  
pp. 653-660 ◽  
Author(s):  
Wei-Ping Zhang ◽  
Dan Yang ◽  
Xian-Min Song ◽  
Xiong Ni ◽  
Jie Chen ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Acute Myelogenous Leukemia ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Myelogenous Leukemia ◽  
Acute Myelogenous ◽  
Blood Stem Cell Transplantation

scholarly journals ID3012 Evaluation of HLA-identical sibling allogenic peripheral blood stem cell transplantation for acute myelogenous leukemia at BTH, Vietnam

2017 ◽  
Vol 4 (S) ◽  
pp. 24
Author(s):  
Man Van Huynh
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Myelogenous Leukemia ◽  
Graft Versus Host ◽  
Acute Myelogenous ◽  
Blood Stem Cell Transplantation

Background: the purposes of this study were to assess the efficacy of HLA-identical sibling allogenic peripheral blood stem cell transplantation in the treatment for acute myelogenous leukemia (AML) at Blood transfusion and hematology hospital at Ho Chi Minh city.   Methods: retrospective study, case series.   Results: from June 2005 to September 2016, there were 47 AML patients included 24 males and 23 females, with median age was 36 years old. Engraftment was achieved in 47 patients (100%). The median number of transfused CD34+ cells was 7.5 x 106/kg. The median time for neutrophil engraftment and platelet engraftment were 11 ± 2.8 days and 12.5 ± 10.1 days respectively. Oral mucositis occurred in 38 patients (80.9%), febrile neutropenia in 42 patients (89.4%), acute graft-versus-host disease (aGvHD) in 14 patients (29.8%), chronic graft-versus-host disease (cGvHD) in 10 patients (21.3%), and VOD in 6 patients (12.8%). Transplant-related mortality (TRM) was 4 patients (8.5%). Median follow-up time was 52.26 months. Patients remained alive were 27 (57.4%). The 5-year overall survival (OS) and disease-free survival (DFS) were 55% and 54% respectively.   Conclusion: HLA-identical sibling allogeneic blood stem cell transplantation can reconstruct hematopoiesis quickly and is a favorable therapeutic method for AML patients. Further development and improvement of hematopoietic stem cell transplantation techniques along with graduated and individualized therapy are expected to provide better outcomes and improved quality of life for AML patients.

Nonmyeloablative Peripheral Blood Stem Cell Transplantation for Chronic Myeloid Leukemia in Chronic and Advanced Phases.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 5041-5041
Author(s):  
Jia-Hua Ding ◽  
Yan Ma ◽  
Bao-An Chen ◽  
Gang Zhao ◽  
Jun Wang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Chronic Phase ◽  
Blood Stem Cell ◽  
Myelogenous Leukemia ◽  
Advanced Phase ◽  
Blood Stem Cell Transplantation

Abstract Objective: To study the effect of nonmyeloablative peripheral blood stem cell transplantation(PBSCT) for chronic myelogenous leukemia(CML) in chronic phase(CML-CP) and advanced phase(CML-AP). Methods: Twenty-four CML patients, 16 in CML-CP and 4 in CML-AP underwent nonmyeloablative peripheral blood stem cell transplantation(NST). The conditioning regimen included fludarabine 30mg.m−2.d−1, intravenously(i.v.)×6d, busulphan 4mg.m−2.d−1×2d and CTX 350mg.m−2.d−1×2d combined with or without Ara-C. The donors were HLA-identical (n=20) and 5/6 antigen-matched (n=4). Results: All the patients were successfully engrafted. The mean time needed for increase of the number of neutrophils to more than 0.5×109/L and platelet more than 20×109/L were 13 days and 11.5 days respectively. Among 12 patients, 9 showed complete donor chimerism(CDC) and 3 showed mixed chimerism(MC) at +day 30. At +day 180, 18 patients still alive showed CDC and remained alive after a median follow-up of 24 months (4∼48months). 3 cases died of severe acute GVHD(aGVHD), 1 case of chronic GVHD(cGVHD), 2 cases of interstitial pneumonia(IP) and 1 case of relapse. Conclusion: Nonmyeloablative PBSCT is an effective method for CML patients in chronic phase and advanced phase. Characteristics of 24 CML patients and their donors Patient Age Gender Diagnosis Donor HLA *: unrelated donor 1 40 male CML-AP brother HLA-identical 2 32 male CML-AP brother HLA-identical 3 40 male CML-CP brother HLA-identical 4 40 male CML-CP brother HLA-identical 5 42 male CML-AP brother HLA-identical 6 24 male CML-AP sister HLA-identical 7 55 male CML-CP sister HLA-identical 8 32 male CML-CP brother HLA-identical 9 36 male CML-CP brother HLA-identical 10 46 female CML-AP sister HLA-identical 11 52 female CML-CP brother HLA-identical 12 60 male CML-CP sister HLA-identical 13 45 female CML-CP brother HLA-identical 14 48 male CML-CP brother HLA-identical 15 33 male CML-CP URD* HLA-identical 16 35 female CML-CP URD HLA-identical 17 40 male CML-CP brother HLA-identical 18 34 female CML-AP sister HLA-identical twin 19 54 female CML-CP brother HLA-identical 20 33 male CML-AP URD Subtype mismatched 21 32 male CML-CP URD Subtype mismatched 22 42 male CML-CP URD mismatched 23 50 female CML-CP URD HLA-identical 24 46 male CML-CP brother HLA-identical

Sign in / Sign up

Export Citation Format

Share Document